In little more than five years, German biotechnology company YUMAB (a phonetic play on HUMAB (human monoclonal antibody) in which the “Y” symbolizes the antibody structure) has become a global ...

Human therapeutic antibodies constitute the industry’s fastest-growing therapeutic class. In the US, more than 500 antibodies are in various stages of clinical development, and the number of ...

New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...

Lanadelumab has been found to be effective as long-term prophylaxis in reducing attack frequency in patients with HAE.

Request To Download Free Sample of This Strategic Report @ Catalysts of Market Growth: The buoyant growth trajectory of the global monoclonal antibodies market is propelled by a convergence of ...

Many patients with diabetes mellitus (both type 1 and type 2) require therapy to maintain normal fasting glucose levels. To develop a novel treatment for these individuals, we used phage display ...

Researchers at the Duke Human Vaccine Institute successfully created an HIV vaccine candidate that guides key immune cells ...

Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its fully human antibodies to ...

Antibody humanization involves modifying antibodies from non-human sources, such as mice, to decrease their immunogenicity in human applications. While mouse monoclonal antibodies are specific ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the ...

Antibodies that bind to a previously untargeted portion of the malaria parasite could lead to new monoclonal antibody treatments and vaccines for malaria.